Related Experiment Video

Updated: May 19, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Current therapeutic strategies in cardiorenal syndrome

A Palazzuoli1, A Geyer, A Malandrino

  • 1Department of Internal Medicine, University of Siena, Siena, Italy. palazzuoli2@unisi.it

Minerva Cardioangiologica
|August 4, 2012
PubMed

Insights

Cardiorenal syndromes (CRS) involve heart and kidney dysfunction. Further studies are needed to optimize drug dosages for chronic heart failure and renal impairment to improve patient outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Cardiorenal syndromes (CRS) describe conditions where heart dysfunction impacts kidneys, or vice versa.
  • Primary organ dysfunction often leads to secondary injury in the other organ.
  • Current guidelines lack specific recommendations for CRS patients with renal impairment.

Purpose of the Study:

  • To highlight the need for further research into optimal drug titration and dosages for CRS.
  • To address the lack of demonstrated renal improvement in recent acute heart failure trials.
  • To guide therapeutic strategies for improving renal function and reducing mortality in CRS.

Main Methods:

  • Review of current literature and clinical trial outcomes in cardiorenal syndromes.
  • Analysis of treatment guidelines for acute heart failure syndromes (AHFS) concerning renal impairment.
  • Identification of knowledge gaps regarding drug efficacy and safety in CRS.

Main Results:

  • Recent clinical trials in acute heart failure syndromes (AHFS) have not shown improvements in renal function or perfusion.
  • Existing guidelines do not offer specific recommendations for AHFS patients with kidney dysfunction.
  • There is a clear need to investigate drug dosages and potential adverse effects in CRS.

Conclusions:

  • Optimizing drug therapy to improve renal function, reduce neurohormonal activation, and enhance renal blood flow is crucial.
  • Such therapeutic improvements could significantly decrease mortality and hospitalization rates in CRS patients.
  • Further clinical trials are essential to establish evidence-based treatment protocols for cardiorenal syndromes.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.